The 675‐nm wavelength for treating facial melasma
Skin Research and Technology · 2023
DOI: 10.1111/srt.13434 ↗Kurz gefasst
Fachartikel in der Zeitschrift Skin Research and Technology, 2023. Verfasst von Luigi Coricciati und 4 weiteren Autor:innen. Beteiligte Einrichtung: Coricciati Medical Group, Martano, Italy. Hauptthemen laut MEDLINE: Inflammation, Melanosis. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Melasma is an acquired skin problem. It characterises sun‐exposed areas, particularly on the face, with irregular borders and bilateral distribution. With this study, we want to strengthen the scientific literature regarding the use of a 675‐nm laser device for the treatment of women and men with facial melasma pigmentary and vascular symptoms. Materials and methods Eighteen patients were treated for facial melasma. A total of three sessions at 30‐day intervals were performed with a 675‐nm laser device. A five‐point Global Aesthetic Improvement Scale was used to separately assess the improvement of the patient's skin 3 months after the last treatment (T1) compared to baseline (T0). The pain during treatment was measured using a Visual Analog Scale of 10 points. The non‐ablative laser system used emits red light with a wavelength of 675 nm through a 13 × 13 mm scanning system.
Results
At T 1 , a consistent improvement in the pigmentary and vascular components was visible. This is always combined with a considerable reduction in vascular expression.
Conclusion
Our research shows that individuals with Fitzpatrick phototypes II to III can treat facial melasma with the 675‐nm laser source system without risk. Due to its interaction with melanin, collagen and haemoglobin chromophores, as well as its excellent capacity to penetrate tissues with less heating, this system is promising in the treatment of pigmentary and vascular illnesses such as melasma. The great success of the technology we used came from the reduced levels of inflammation produced after the treatments and the low energy level implied.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Coricciati Medical Group, Martano, Italy.
- El.En. Group, Calenzano, Italy.
ORCID-Profile: Beatrice Marina Pennati
Zitieren
APA
Coricciati, L., Gabellone, M., Donne, P. D., Pennati, B. M., & Zingoni, T. (2023). The 675‐nm wavelength for treating facial melasma. Skin Research and Technology. https://doi.org/10.1111/srt.13434
Vancouver
Coricciati L, Gabellone M, Donne PD, Pennati BM, Zingoni T. The 675‐nm wavelength for treating facial melasma. Skin Research and Technology. 2023. doi:10.1111/srt.13434
BibTeX
@article{Coricciati2023,
author = {Coricciati, Luigi and Gabellone, Maddalena and Donne, Pantalea Delle and Pennati, Beatrice Marina and Zingoni, Tiziano},
title = {The 675‐nm wavelength for treating facial melasma},
journal = {Skin Research and Technology},
year = {2023},
doi = {10.1111/srt.13434}
}
EUVIMED